Drug Trial Radar · NCT07063875
Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Jun 1, 2025
Primary completion
Sep 1, 2027
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- St Vincent's Hospital, SydneyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A recent clinical trial found that after 36 months, patients taking tebentafusp had a median survival of 21.6 months, compared to 16.9 months for those in the control group. Since recruitment for tebentafusp in metastatic uveal melanoma (mUM) has ended, a new trial is starting to test whether adding IL-2 can help overcome resistance to tebentafusp and improve its effectiveness. This study aims to answer: 1. Can combining tebentafusp with IL-2 improve tumor response and overall survival? 2. What are the benefits and side effects of this combination therapy? All participants will receive both IL-2 and tebentafusp in a 28-day treatment cycle. The dosing schedule is as follows: Cycle1: Day1-3 IL-2 Day4 Tebentafusp Day 10 IL-2 Day 11 Tebentafusp Day 17 IL-2 Day 18 Tebentafusp Day 24 IL-2 Day 25 Tebentafusp Cycle 2 \& thereafter Day 1 IL-2 Day 2 Tebentafusp Day 8 IL-2 Day 9 Tebentafusp Day 15 IL-2 Day 16 Tebentafusp Day 22 IL-2 Day 23 Tebentafusp
Conditions
- Uveal Melanoma
- Metastatic Uveal Melanoma
- Metastatic Uveal Melanoma in the Liver
Interventions
AldesleukinDrug
IL-2 in combination with Tebentafusp
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of Combination therapyTime frame: Through study completion, approx 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Kinghorn Cancer Centre, St. Vincent's Hospital
Sydney, New South Wales, Australia · Recruiting
Alfred Hospital
Melbourne, Victoria, Australia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.